Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. - Wikidata - awgldk - TriplyDB

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.

http://www.wikidata.org/entity/Q43693354

about

Functional neuroimaging in Parkinson's disease The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway.Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease Noradrenaline and Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat Novel pharmacological strategies for motor complications in Parkinson's disease.Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease Drug Insight: new drugs in development for Parkinson's disease.Specificity and impact of adrenergic projections to the midbrain dopamine system.Antineoplastic activity of idazoxan hydrochloride.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments Advances in non-dopaminergic treatments for Parkinson's disease Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Locus coeruleus.Which dyskinesia scale best detects treatment response?MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Norepinephrine: the next therapeutics frontier for Parkinson's disease.The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease.The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms.The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.Dyskinesia in Parkinson's disease treated by deep brain stimulation once electrode position was revised: case report.Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

P2860

Q27013767-006AA5E9-4F16-437F-93D4-FDE9CEC6BB2B Q28477041-60F748A3-802E-4232-879D-050C6A2FE6E6 Q30479999-EE74DF3A-B41A-44C4-827A-FADB4A6A0A88 Q33591426-A47DF81E-4A9F-494D-AA79-37CC7B611E51 Q33918393-2B28AF36-C343-4BBA-A865-8601822098E4 Q34572608-BA0ABD98-44AB-4A53-BE84-C09B628ADEFB Q35013240-8C3C82FB-D561-47A1-AF79-DC2335D84942 Q35589979-7B4B50DA-1472-4802-9344-CB5708098BAB Q35624275-9C7F3ECE-9F06-4AD8-AE0A-2A208291194A Q35738678-96A3E345-F09E-4FD5-938C-CFBA3C8B59D4 Q35815701-E3247EE2-BEA9-4104-8411-97E451C4B530 Q36120761-C152BC4C-BAC5-4F8C-98D2-E37598EF8D52 Q36227392-890223AC-9731-4594-A527-4B5CDB721798 Q36631654-9A60110E-46BC-4DAB-B056-AB4AA53C0DCB Q36932568-9334B49D-B8C5-484B-8AE3-A14F3EA20DC8 Q37310452-E20637AC-BD49-4566-81D7-66265D5F89B8 Q37506507-0370D26B-4D6B-4CC9-B182-5DD5B18DA265 Q37924629-A9D4FC9E-9EAB-4048-BFD6-21B8F104B91F Q38156760-F85B68F3-868C-4D15-86C7-2E9615C469C3 Q38218083-1B9D4F82-500D-496C-9139-F0B5ED7DC672 Q38245731-B2948A9D-BAB5-4ED1-9C14-67582308E506 Q38258228-C16D6C83-DA3C-44DD-85FB-CD338E3EA159 Q38262418-C0BA8987-DCA8-4900-AF78-6BC692DC86B2 Q38284574-AE011626-D53F-4D4F-B195-6D72C7E3D395 Q38355582-45FAB3D0-9961-43D9-A586-EDB08C4CFB92 Q38811387-84DCF782-2831-420E-B6F0-25E2AF9B435A Q39422119-25CEC210-8819-4D44-B0FA-9145A0E7E19B Q39471220-2F86C6E2-2D5C-404E-ABE2-476487A4FBB7 Q39906818-276D2714-0147-4A5C-A534-4798DC3DF731 Q41645312-41AE4DEC-6C24-45A3-A2AA-E5F20D946334 Q41975512-B5DF40BA-FD59-4985-A9E8-81877BAEB399 Q42248817-70EFD547-2DC7-4BD5-A109-E42D41EA78EB Q44367391-596C486B-10F0-4143-8063-4B6D56D4DE3A Q47752902-150737E1-27B0-411A-84CD-6B99B390C17C Q48121370-2F948E9C-F3D5-4DDC-B64E-AB4C79526D7D Q48586476-93AC055D-E6AF-4FF7-BB45-C00F75E0EFBC Q53542537-4C5290D5-1ABB-4784-A3DC-507AD30540D8

P2860

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.

http://www.wikidata.org/entity/Q43693354

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@en

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@nl

type

label

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@en

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@nl

prefLabel

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@en

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@nl

P1433

Q43693354-BA051817-298B-4042-A4A4-61A2CC07E5CA

P1476

Q43693354-8F661315-B408-42CE-8593-6A3612032323

P2093

Q43693354-0E15D6FC-5CAE-4616-BCC3-7AC5CEF873E7

Q43693354-2473C0A3-FA97-4AEE-BF03-2F80F5C23F01

Q43693354-4313FCEB-5D54-4407-A8F9-5A56F48459E5

Q43693354-465D20B9-AD0F-41AC-95CE-598832A636C6

Q43693354-B0F460EC-19F9-4235-AB96-DD523B762CBB

Q43693354-B9855F1E-B786-4E2D-8176-01F2E99E6EAB

Q43693354-BD759386-9118-49E9-9203-27D2592D836B

Q43693354-C19A6103-499C-4B70-B510-3D241AA8DC51

Q43693354-CEAC4986-B48D-409C-B152-1C4D22525B08

Q43693354-E0441D2E-FF12-4C6A-829B-3C3B904E435E

P2860

Q43693354-0536918F-7F29-40B2-859C-8FB55AF01B49

Q43693354-1ABED90C-1CCD-4963-AD40-2F16EDBDCD26

Q43693354-211E4525-A164-45F5-A604-9C2069D57AAB

Q43693354-29785598-1298-4015-94BA-708AE750E5B4

Q43693354-31340D2E-F6FE-4756-865E-9DD24056FF3A

Q43693354-36CC514A-4240-40CA-8EC0-2CC4B3096D64

Q43693354-3F89F0FC-D0E7-4EED-9FF1-8E69C894909F

Q43693354-457B017D-8887-4210-B9C1-411753CE0AD1

Q43693354-4C550ABA-58AD-4BED-B556-042AAD89F4CD

Q43693354-557D1CE3-E2EF-4467-BD9C-D425484833CE

P304

Q43693354-D459F152-3FB4-4F91-ADC6-79A118911786

P31

Q43693354-5F45E926-666D-458D-B769-521A5491AD27

P356

Q43693354-838C6B32-E155-42E9-AD70-C40D5D9374B3

P407

Q43693354-BE75D8DE-ADDF-4466-9EBA-928E02B92FC8

P433

Q43693354-8B2B529B-C82D-4D26-8F2D-37B29A7DEF55

P478

Q43693354-E21B6CCF-2465-494F-B5DB-21AB6F10F3FB

P50

Q43693354-8E9D194C-D740-42CD-9BC4-E3613963D907

Q43693354-BE40A382-C841-4641-927A-DE6FBF2C9D74

P577

Q43693354-4A8579A5-980A-4DD8-A7AE-7A1AD3E88C61

P698

Q43693354-09EBD9C3-9B6F-4C72-B73A-414D0062B35F

P921

Q43693354-63C846F1-7B51-4DAC-B7EB-FA02451FC1AF

Q43693354-C000DA52-C8D7-44DC-8309-B4349C8BC7C3

P356

P1433

Movement Disorders

P1476

Idazoxan, an alpha-2 antagonis ...... ents with Parkinson's disease.

@en

P2093

Bejjani B

http://www.w3.org/2001/XMLSchema#string

Bonnet AM

http://www.w3.org/2001/XMLSchema#string

Brefel-Courbon C

http://www.w3.org/2001/XMLSchema#string

Descombes S

http://www.w3.org/2001/XMLSchema#string

Fabre N

http://www.w3.org/2001/XMLSchema#string

Montastruc JL

http://www.w3.org/2001/XMLSchema#string

Peyro-Saint Paul H

http://www.w3.org/2001/XMLSchema#string

Rascol O

http://www.w3.org/2001/XMLSchema#string

Thalamas C

http://www.w3.org/2001/XMLSchema#string

Vidailhet M

http://www.w3.org/2001/XMLSchema#string

P2860

Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Parkinsonism: onset, progression and mortality

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.

Imidazoline receptors and their endogenous ligands.

Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase.

P304

708-713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.1143

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Isabelle Arnulf

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11481696

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease